Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 25Other hematologic neoplasm 15Lymphoid 3Other neoplasm 2Classical hematology 2Sarcoma 1Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 767Lymphoma 713Leukemia, Lymphocytic, Chronic, B-Cell 560Lymphoma, Follicular 515Lymphoma, Large B-Cell, Diffuse 440Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Recurrence 317Lymphoma, B-Cell 294Neoplasms 261Lymphoma, Mantle-Cell 251Leukemia 231Multiple Myeloma 189Hodgkin Disease 179Leukemia, Myeloid, Acute 178Lymphoma, B-Cell, Marginal Zone 135Lymphoma, T-Cell, Peripheral 119Burkitt Lymphoma 105Myelodysplastic Syndromes 101Hematologic Neoplasms 100Lymphoma, T-Cell, Cutaneous 88Waldenstrom Macroglobulinemia 84Leukemia, B-Cell 79Lymphoma, T-Cell 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 65Lymphoproliferative Disorders 57Hematologic Diseases 57Melanoma 54Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 51Mycosis Fungoides 49

Interventions

ponatinib 2Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Bone Marrow Diseases × Lymphoid × Clear all
NCT06034275 2024-11-15

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Vincerx Pharma, Inc.

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Burkitt Lymphoma, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡